Back to News
Market Impact: 0.32
Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted Takeda's New Drug Application for zasocitinib under priority review for treating adults with moderate-to-severe plaque psoriasis. Priority review accelerates the agency's assessment timeline and represents a positive regulatory milestone for Takeda's dermatology pipeline, though approval and commercial potential remain uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
TAK0.72
More News
- Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
- Tencent, Visa deepen payments push in China after regulatory green light
- Healey Defends UK Budget, Warns 'Tough Decisions' Ahead
- Kalshi, co-founders hit with criminal charges in US state of Utah
- Trump methane policy rollback may have minimal impact on crude prices, EPA says
- Nvidia's $12.9 billion Hugging Face deal draws DOJ scrutiny